KIDNET PUBLICATIONS

**Octreotide use and safety in infants with hyperinsulinism**
Ann W. McMahon1*, Gerold T. Wharton1, Paul Thornton2 and Diva D. De Leon3
1Office of Pharmacoepidemiology and Drug Safety 2017; 26: 26–31
Published online 2 December 2016 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.4144

**Pediatric post-marketing safety systems in North America: assessment of the current status†**
Ann W. McMahon1*, Gerold T. Wharton1, Renan Bonnel1, Mary DeCelle1, Kimberley Swank2, Daniela Testoni3, Judith U. Cope1, Phillip Brian Smith3, Eileen Wu2 and Mary Dianne Murphy1
Pharmacoepidemiology and Drug Safety 2015; 24: 785–792
Published online 22 June 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3813

**Serious Adverse Events During On-Label or Off-Label Use of Fentanyl and Azithromycin in Children in Intensive Care Units**
Debbie Avant, RPh1, Gerold T. Wharton, MS1, Ashley White1, Renan Bonnel, PharmD, MPH1, Mary DeCelle1, Edwin Doe, MD2, Mohammed H. Al Jarwi, MD2, Sarah Donegan, PharmD, BCOP3, Norman Fenn, PharmD, BCPS3, Allison Lardieri, PharmD, BCPS4, An Nguyen, PharmD4, Beena G. Sood, MD. MS5, Carol Taketomo, PharmD6, Phuong Lieu, PharmD6, Lilly Yen, PharmD6, Kazeem Oshikoya, MD, PhD7, Sara L. Van Driest, MD, PhD7, Ann W. McMahon, MD, MS

1. Office of Pediatric Therapeutics, Food and Drug Administration, Silver Spring, MD, USA,
2. INOVA Children's Hospital, Falls Church, VA, USA,
3. Children's National Health System, Washington, DC, USA, Washington, DC, USA,
4. University of Maryland Children's Hospital, Baltimore, MD, USA,
5. Children's Hospital of Michigan, Detroit, MI, USA,
6. Los Angeles Children's Hospital, Los Angeles, CA, USA,
7. Vanderbilt University School of Medicine, Nashville, TN, USA.